Results 271 to 280 of about 181,087 (306)

Are All Chimeric Antigen Receptors Created Equal?

Journal of Clinical Oncology, 2015
In the report accompanying this article, Kochenderfer et al discuss the efficacy of autologous T cells expressing a CD19-specific chimeric antigen receptor (CAR) in patients with relapsed diffuse large B-cell lymphoma. Although previous reports have demonstrated significant antitumor activity in low-grade B-cell malignancies and B-cell acute ...
Jae H, Park, Renier J, Brentjens
openaire   +2 more sources

Chimeric antigen receptors

Nature Biotechnology, 2022
openaire   +2 more sources

Chimeric antigen receptor therapy meets mRNA technology

Trends in Biotechnology
Genetically engineered immune cells expressing chimeric antigen receptors (CARs) have emerged as a new game changer in cancer immunotherapy. The utility of CAR T cell therapy against hematological malignancies has been validated in clinical practice. Other CAR immune cells are currently under investigation to improve the potency of CAR therapy in solid
Jiacai Wu, Weigang Wu, Boping Zhou, Bin Li   +3 more
openaire   +2 more sources

Chimeric antigen receptor therapy in hematologic malignancies

JAAPA
ABSTRACT Chimeric antigen receptor (CAR) T-cell therapy has led to significant advances in the treatment of blood cancers such as leukemia, lymphoma, and multiple myeloma, and now shows promise for solid tumors. This type of immunotherapy can achieve high response rates in patients with hematologic malignancies, but carries serious adverse ...
Elizabeth, Brownlee, Melissa, Turley, Heather, Nations   +2 more
openaire   +2 more sources

Chimeric antigen receptors

Nature Biotechnology, 2020
openaire   +2 more sources

Chimeric antigen receptor Treg therapy in transplantation

Trends in Immunology
In the quest for more precise and effective organ transplantation therapies, chimeric antigen receptor (CAR) regulatory T cell (Treg) therapies represent a potential cutting-edge advance. This review comprehensively analyses CAR Tregs and how they may address important drawbacks of polyclonal Tregs and conventional immunosuppressants.
Siawosh K, Eskandari, Andrea, Daccache, Jamil R, Azzi   +2 more
openaire   +2 more sources

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023

exaly  

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Boris Böll, Victoria Metaxa   +2 more
exaly  

Breast Cancer Statistics, 2022

Ca-A Cancer Journal for Clinicians, 2022
Hyuna Sung, Kimberly D Miller, Rebecca L Siegel   +2 more
exaly